Content labelled as: Research

MS Society Research Talk has been rescheduled:

Blog post

Research Talk

Date: Monday 13th November 2017, Time: 10:30 - 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ

European Commission reverses decision on drug, following QMUL research

Blog post

Source Queen Mary University of London:

A drug for multiple sclerosis (MS) has been granted a license by the European Commission, following evidence from Queen Mary University of London (QMUL) that it improves patients’ quality of life and is safer than previously thought.

Gut Microbes May Influence Multiple Sclerosis Progression

Blog post

Source University of California San Francisco:

Researchers at UC San Francisco have identified specific gut microbes associated with multiple sclerosis (MS) in human patients, and show that these microbes take part in regulating immune responses in mouse models of the disease.

Cladribine: NICE looking at new treatment for MS

Blog post

Source MS Society:

The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS.

The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in...

Drugs in development

Blog post

Source MS Trust:

The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments with many being rejected on safety, efficacy or quality grounds.

Pancreas Secretes Factor That Can Rejuvenate Damaged Neuron Coating, Mouse Study Reports

Blog post

Source Multiple Sclerosis News Today:

A substance that the pancreas secretes can promote the regeneration of the protective nerve-cell coating that is damaged in multiple sclerosis, a mouse study shows.

Cladribine (Mavenclad) gets European licence for highly active relapsing MS

Blog post

Source MS Trust:

The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad)for the treatment of adults with highly active relapsing multiple sclerosis. This follows a recommendation from the European Medicines Agency in June that a licence should be granted.

Nortis Awarded $688K Grant from NIH to Develop ‘Living’ Model of Blood-Brain Barrier for Research

Blog post

Source Multiple Sclerosis News Today:

Nortis, a Seattle-based biotech company, has received a $688,000 grant by the National Institutes of Health (NIH) to create a living, 3-D model of the human blood-brain barrier that will be used for laboratory testing to accelerate drug development and lessen the likelihood of failure in clinical trials.

Common stomach bacteria can reduce MS symptoms in mice

Blog post

Source MS Society:

Researchers have found that common gut bacteria can suppress MS symptoms in mice.

CANCELLED: MS Society Research Talk 9th September 2017 at the Hilton Hotel Reading

Blog post

Please note this event has been cancelled.

Pages

Subscribe to Content labelled as: Research